we have a significant opportunity to strengthen our oncology business with the launch of Blenrep in half-two, 2025. We filed for approval in the U.S., EMA, and Japan in the quarter. Next slide ...

Blenrep extended the time to disease progression ... in the first nine months of 2023. Prior to its launch, GSK had suggested it could eventually become a £3 billion blockbuster, assuming it ...

Blenrep (belantamab mafodotin ... option for relapsed and refractory multiple myeloma. It’s a key new launch for GSK as it tries to rebuild its oncology business under chief scientific officer ...

Sales of the jab for respiratory syncytial virus (RSV), previously a key driver of vaccine sales which saw an extremely ...

Sales of the jab for respiratory syncytial virus (RSV), previously a key driver of vaccine sales which saw an extremely successful launch last ... next year.” Blenrep, a treatment for cancer ...

Sales of the jab for respiratory syncytial virus (RSV), previously a key driver of vaccine sales which saw an extremely successful launch last year ... built into GSK’s portfolio and performance”.